Ding Yang

Dr. Ding Yang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
DYDing Yang
Ding Yang
QHQian Hong
Qian Hong
CZChenguang Zhao
Chenguang Zhao
JMJuwei Mu
Juwei Mu
This study aimed to use a new special inventory for lung surgery patients to evaluate postoperative symptoms and functional status and to identify factors that may affect these after uniportal video-assisted thoracoscopic surgery (VATS). In this single-center longitudinal cohort observational study, we used a new scale, the perioperative symptom assessment for lung surgery (PSA-Lung), to evaluate the recovery from symptoms and the functional status of patients undergoing uniportal VATS. We divided patients into two groups, according to patients’ symptom scores, and compared the clinical characteristics between the two groups under each item. Then, we conducted a qualitative interview regarding coughing in postoperative week 4. Exactly 104 patients were enrolled in this study. The two highest-scoring patient-reported outcome (PRO) items were “shortness of breath” and “coughing” in the fourth week after surgery. Thirty-one patients reported that “coughing” severely influenced their lives in postoperative week 4. Using the PSA-Lung inventory, we found that “shortness of breath” was the worst symptom in postoperative week 4. Although “coughing” was not the most important symptom in the early postoperative period, it affected some patients’ lives in postoperative week 4. Therefore, further research is required to determine the optimal cut-off point for coughing.

13 December 2024 in Thoracic Cancer
Verified
Journal Article
Open access
XWXing Wei
Xing Wei
HYHongfan Yu
Hongfan Yu
BKBellinda King‐Kallimanis
Bellinda King‐Kallimanis
YLYangjun Liu
Yangjun Liu
LHLin Huang
Lin Huang
QSQiuling Shi
Qiuling Shi
Background: The effects of lobectomy at various lung sites on postoperative function and recovery vary. This study aimed at assessing the long‐term impact of upper versus lower lobectomy on patients' postoperative daily function by analyzing patient‐reported outcomes.Methods: This multicenter prospective cohort study enrolled patients from six hospitals in China. Functional impairments and symptom severity were measured using the MD Anderson Symptom Inventory‐Lung Cancer. A mixed‐effects linear model was employed to analyze the average trajectories of each functional item and the top five symptoms over the first year following surgery between patients undergoing upper and lower lobectomy. The median recovery days for daily function were estimated using the Kaplan–Meier method, with the log‐rank test comparing differences between upper and lower lobectomy.Results: Two hundred twenty‐six patients met the final analysis criteria, with 137 undergoing upper and 89 undergoing lower lobectomies. Those in the lower lobectomy group reported significantly greater interference with daily activities (estimate = 0.872, SE = 0.306, p = 0.004), mood (estimate = 0.667, SE = 0.297, p = 0.025), and work (estimate = 0.856, SE = 0.358, p = 0.017), indicating a more pronounced impact on postsurgical functional recovery compared to the upper lobectomy group within the first year after surgery. They also experienced longer median recovery times for daily activities (15 vs. 4 days), mood (6 vs. 3.5 days), and walking (7 vs. 4 days) compared to the upper lobectomy group.Conclusions: Within the first year after surgery, lower lobectomy patients experienced greater impairment in daily functions and required longer recovery times compared to upper lobectomy patients.Trial Registration: NCT03341377

19 September 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
XWXing Wei
Xing Wei
YLYangjun Liu
Yangjun Liu
HYHongfan Yu
Hongfan Yu
WDWei Dai
Wei Dai
DYDing Yang
Ding Yang
QSQiuling Shi
Qiuling Shi
Introduction Although molecular testing is crucial for many patients with lung cancer, the decision to carry out molecular testing is not easy to make in actual clinical scenarios. Using a specific decision aid (DA) to conduct shared decision-making (SDM) may help ameliorate this problem. However, no DA currently exists for lung cancer molecular testing (DA_LCMT). We aim to develop an evidence-based, iteratively refined DA, which may facilitate SDM and improve the quality of SDM. Methods and analysis After considering the Ottawa Decision Support Framework, International Patient Decision Aid Standards and Food and Drug Administration guidance about methods to identify what is important to patients, semistructured interviews with qualitative research methods will be used to generate the decision-making needs of patients with lung cancer diagnosed with lung adenocarcinoma by intraoperative frozen pathological sections. Input will be provided by patients and other stakeholders, including thoracic surgeons, nurses, hospital administrators, molecular testing company staff and insurance company staff. Then, a modified Delphi method will be used to develop the DA_LCMT V.1.0 (DA_LCMT 1.0). Structured interviews with qualitative research methods will be used in the cognitive debriefing (alpha tests) and field testing (beta tests) to revise and improve the DA_LCMT from version 1.0 to the final version, version 3.0. Descriptive statistics will be used to summarise the baseline characteristics of the patients and other stakeholders. Qualitative data will be analysed using the three steps of grounded theory: generate a codebook, update the codebook and create a comprehensive list of related items. Ethics and dissemination Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital approved this study. This protocol is based on the latest version 1.0, dated 31 October 2021. The study was also approved by the Ethics Committees of The Third People’s Hospital of Chengdu, Zigong First People’s Hospital and Jiangyou People’s Hospital. The results of this study will be presented at medical conferences and published in peer-reviewed journals. Trial registration number NCT05191485.

26 April 2023 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
PDF file
DYDing Yang
Ding Yang
XWXing Wei
Xing Wei
QHQian Hong
Qian Hong
CZChenguang Zhao
Chenguang Zhao
JMJuwei Mu
Juwei Mu
Background Patients undergoing lung tumor surgery may experience various complications after discharge from the hospital. Using patient-reported outcomes (PROs), this study attempted to identify relevant indicators of postdischarge complications after lung tumor surgery and develop a predictive nomogram model to evaluate the risk for individual patients. Methods Patients who underwent lung tumor surgery between December 2021 and June 2022 were included in this study. PROs were assessed using the Perioperative Symptom Assessment for Lung Surgery scale and were assessed preoperatively at baseline, on postoperative day 1 (POD1) 1 to POD4, and then weekly until the fourth week. A random forest machine learning prediction model was built to rank the importance of each PRO score of patients on POD1 to POD4. We then selected the top 10 variables in terms of importance for the multivariable logistic regression analysis. Finally, a nomogram was developed. Results PROs, including coughing (POD3 and POD4), daily activity (POD1), and pain (POD1 and POD2), were associated with postdischarge complications in patients undergoing lung tumor surgery. The predictive model showed good performance in estimating the risk of postdischarge complications, with an area under the curve of 0.833 (95% confidence interval: 0.753–0.912), while maintaining good calibration and clinical value. Conclusion We found that PRO scores on POD1 to POD4 were associated with postdischarge complications after lung tumor surgery, and we developed a helpful nomogram model to predict the risk of postdischarge complications.